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Development of a high-performance liquid chromatography
method for warfarin detection in human plasma
Yung An CHUA1, Wan Zaidah ABDULLAH2, Siew Hua GAN3

Aim: Most of the high-performance liquid chromatography (HPLC) methods that have been developed to measure
warfarin levels use the preextraction spiked internal standard method. We developed a new liquid-liquid extraction
(LLE) and reversed-phase HPLC method that uses a postextraction spiked internal standard for the determination of
plasma warfarin.
Materials and methods: The effect of varying the 1) mobile phase pH, 2) type and composition of organic solvents, 3)
type and concentration of buffer solutions, 4) column temperatures, 5) flow rates, 6) organic modifier, and 7) ultraviolet
wavelengths were tested.
Results: Optimum separation was achieved by using 30:70 (v/v) acetonitrile and potassium dihydrogen orthophosphate
(0.01 M) at pH 6.5 without the addition of an organic modifier at 300 nm. The column temperature was fixed at 30 °C
and the flow rate at 1.0 mL/min. Phenylbutazone was the most suitable internal standard. For LLE, the optimum plasma
pH was 4.5, using 2 volumes of 2.5 mL of diethyl ether. The average retention times of warfarin and phenylbutazone
were 7 and 11 min, respectively.
Conclusion: The postextraction spiked internal standard method saved a significant amount of development time and
gave an excellent recovery of nearly 90%. This method was successfully tested using spiked human plasma. On the
whole, the developed method is simple, economical, and suitable for routine application.
Key words: Method development, HPLC, warfarin, postextraction

Introduction
Warfarin is one of the most commonly administered
oral anticoagulants used in the prophylactic treatment
of various thromboembolic disorders. Due to its wide
interindividual variability and narrow therapeutic
index, optimal determination of its dose is difficult
to achieve and suboptimal dosings remain the norm
(1). Because different ethnic groups may show
different responses to warfarin (2), many researchers
throughout the world have developed their own
detection methods for warfarin pharmacokinetic
studies for their local populations.

Some
researchers
have
utilised
gas
chromatography-mass spectrometry (GC-MS) to
quantitate warfarin levels in both biological samples
and pharmaceutical products (3-5). However, these
methods require prior derivatisation steps, which are
tedious. The heating process for sample volatilisation
may also contribute to some sample loss.
Other reports include the use of high-performance
liquid chromatography (HPLC) analyses coupled
with ultraviolet (UV) (6-8) and fluorescence (9)
detectors. Another group of researchers achieved
an exceptionally low limit of detection (0.3 ng/mL)
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by utilising a mass spectrometer detector (10) due
to its high sensitivity. However, not all laboratories
have mass spectrometry or fluorescence detectors.
Therefore, HPLC coupled with a UV detector remains
an easier and cheaper option that is popular among
many researchers.

control the equipment as well as integrate the peaks
in the chromatograms. The analytical column was a
Purospher® STAR (250 × 4.6 mm i.d., 5 μm) endcapped
RP-18 column (Merck, Darmstadt, Germany),
coupled with a guard cartridge (Purospher® STAR; 4
× 4 mm i.d., 5 μm) (Merck).

Chiral separation of the (S)- and (R)-warfarin
enantiomers is useful for drug metabolism studies.
Correlation between genetic variations of cytochrome
P450 2C9 gene (CYP2C9) and warfarin clearance can
be elucidated by measuring the plasma level of (S)and (R)-warfarin in individuals that have different
CYP2C9 genotypes (11). However, a chiral separation
method can be expensive as special β-cyclodextrin
or silica-based chiral columns are needed (12,13).
Furthermore, it is not always necessary to run chiral
separations if the HPLC result is to be correlated with
a parameter such as the International Normalised
Ratio (INR) that is influenced by both (S)- and (R)warfarin (7,8).

Chemicals and reagents

The pretreatment of samples is another important
step in methodology development as it also influences
the sensitivity of the method. The most common
pretreatment methods are liquid-liquid extraction
(LLE) and solid-phase extraction (SPE). SPE has an
advantage over LLE in that it can easily be automated
and consumes less organic solvents. However, LLE
is preferred over SPE by some researchers because
SPE may suffer from batch-to-batch manufacturing
variations that influence reproducibility (14).
Furthermore, SPE is a more expensive option due to
the need for single-use columns.
In this research, our goal was to develop a new but
simple HPLC method coupled with a UV detector and
to find a new extraction method for plasma warfarin,
which can be used routinely in the laboratory for the
detection of warfarin plasma samples.
Materials and methods
Equipment
The HPLC machine consisted of the Waters 2695
HPLC system (Milford, MA, USA) integrated with
a column oven, an autosampler, and a vacuum
degasser. The detector was a Waters 2996 PDA
detector (Milford, MA, USA). Empower Pro® 5.0
software (Waters, Milford, MA, USA) was used to

The warfarin standard was purchased from
US Pharmacopeia (Rockville, MD, USA). The
diethylstilbestrol, eserine, indomethacin, lignocaine,
phenylbutazone, and sulphadiazine standards were
purchased from Sigma Chemical Company (St Louis,
MO, USA).
The
acetonitrile
(ACN),
chloroform,
dichloromethane, ethyl acetate, hexane, methanol
(MeOH), and sulphuric acid (H2SO4) were from
Merck, while the diethyl ether and formic acid were
from Fisher Scientific (Leicestershire, UK).
The potassium dihydrogen orthophosphate
(KH2PO4), sodium dihydrogen orthophosphate
(NaH2PO4), and sodium hydroxide (NaOH) were
purchased from Ajax Chemicals (Auburn, NSW,
Australia), and the potassium acetate (CH3COOK)
was from BDH Chemicals (Poole, England).
The ACN, MeOH, and diethyl ether were of
HPLC grades while the other chemicals were of
analytical grades. Deionised water was purified by
using a Millipore Milli-Q® Integral 3/5/10/15 System
(Molsheim, France).
Preparation of standards
Standard stock solutions (1000 μg/mL) of warfarin
were prepared by desiccating the drug standard with
phosphorous pentoxide (Merck) before diluting 10
mg of the desiccated drug standard with 10 mL of
ACN in a conical flask. Working standard solutions
were prepared fresh daily by further dilutions of the
stock solution.
Other drug standards (namely diethylstilbestrol,
eserine, indomethacin, lignocaine, phenylbutazone,
and sulphadiazine in concentrations of 100 μg/
mL) were investigated as possible internal standard
candidates and were prepared by diluting 1 mg of
each drug standard in 10 mL of ACN in a similar
manner.
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Preparation of buffer solutions

(a) Optimisation of the buffer solution pH

All buffer solutions were prepared fresh daily by
diluting the buffer salts in 1 L of deionised water.
The buffer’s pH was adjusted to 6.5 by using a
NaOH (5 M) solution. Before use, the organic
solvents and buffer solutions were filtered through a
polypropylene membrane filter (0.45 μm) (Pall Life
Sciences, Ann Arbor, MI, USA) and degassed for 20
min by using an ultrasonic sonicator (Elma GmbH,
Singen, Germany).

Five different pH levels of the KH2PO4 buffer solution
(pH levels of 3.5, 4.5, 5.5, 6.5, and 7.5) were prepared
in separate reservoir bottles and the solutions were
individually filtered and degassed. With each change
of mobile phase, the column was allowed to be
reequilibrated with at least 20 column volumes of
mobile phase before the experiment was repeated
using different buffer pH levels each time.

Preparation of samples

To investigate the effect of using 2 different types of
organic solvent, MeOH was replaced by ACN in the
mobile phase at the same composition. The peak area
of warfarin produced was then compared in the 2
different procedures.

The plasma was allowed to thaw naturally on the
bench at room temperature. It was then vortexed
for a few seconds to ensure a uniform distribution.
Plasma standards were prepared by spiking 100 μL of
warfarin standard working solution (100 μg/mL) into
1 mL of the thawed plasma, followed by vortexing
the solution for 5 s. The samples were prepared in
duplicates.
Sample extraction
A simple 2-step LLE method was used to extract the
spiked drugs from the plasma standards. The pH
of the plasma standards was adjusted by using 1 N
H2SO4. The plasma was then vortexed for 5 s before
the addition of the organic solvent (2.5 mL). The
mixture was centrifuged at 2000 rpm for 15 min
before separating the organic layer into a v-tube. A
fresh organic solvent (2.5 mL) was again added to
the raffinate and the steps were repeated. The organic
solvents were collected and dried under a gentle
stream of nitrogen gas at 40 °C. The residue was
reconstituted with 100 μL of the internal standard
working solution (10 μg/mL) before being injected
into the HPLC system (10 μL).
Optimisation steps
In the beginning, a 30:70 (v/v) combination of MeOH
and KH2PO (0.01 M) as the mobile phase at 0.75 mL/
min was arbitrarily set for the initial parameters of
the HPLC. The PDA detection wavelength was set at
190-800 nm. The warfarin standard solution (100 μg/
mL) was injected (10 μL) into the HPLC system for
each investigation, and the parameters were varied
according to the steps below.
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(b) Optimisation of the type of organic solvents

(c) Optimisation of the mobile phase composition
Using the 2 different types of organic solvent as noted
above, 2 compositions of organic solvent and buffer
of the mobile phase were tested at ratios of 30:70 and
40:60.
(d) Optimisation of the type of buffers
Using the selected ratios of the mobile phase
composition above, 3 different types of buffers,
namely KH2PO4, NaH2PO4, and CH3COOK buffer
solutions (0.01 M), were further tested.
(e) Optimisation of the buffer concentration
The best buffer solution determined above was
further tested by varying its concentration at 0.01,
0.05, and 0.1 M.
(f) Determination of the suitable internal standard
candidates
Several potential internal standard candidates
(such as diethylstilbestrol, eserine, indomethacin,
lignocaine, phenylbutazone, and sulphadiazine) were
tested (all at 100 μg/mL). They were chosen on the
basis of their similar physicochemical properties to
warfarin.
(g) Optimisation of the column temperature
To investigate the effect of temperature on warfarin’s
peak resolutions, column oven temperatures of 25
and 30 °C were tested.
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(h) Optimisation of the mobile phase flow rate

(m) System suitability tests

For this purpose, 3 flow rates of 0.5, 0.75, and 1.0 mL/
min were investigated and warfarin’s peak area and
retention times were then compared to determine
the flow rate that yielded the largest peak area or the
shortest retention time.

To ensure the quality of the chromatograms produced,
a system suitability test was performed according to
the parameters set by the FDA (15), where:

(i) Optimisation of the type of organic modifier
An organic modifier, acetic acid (1%), was also added
to the mobile phase to determine whether it could
reduce warfarin’s peak tailing.
(j) Optimisation of the PDA detection wavelength
To increase the sensitivity and specificity of the
detection of warfarin and its internal standard,
photodiode array (PDA) detection at individual
specific wavelengths (280, 290, 300, and 309.4 nm)
was tested. A UV spectrum that covered the whole
detection range of the PDA detector (between
190 and 800 nm) was also investigated. Since this
experiment was also designed to test the detection
sensitivity, lower concentrations of warfarin (500 ng/
mL) and phenylbutazone (10 μg/mL) were injected
into the HPLC system.
(k) Optimisation of the suitable plasma pH for LLE
In this experiment, diethyl ether was first arbitrarily
selected as the extraction solvent. In LLE, the pH of
the plasma needs to be varied to suppress the analyte’s
ionisation, thereby allowing its migration from the
aqueous to the organic layer. In this experiment,
the pH of the plasma samples was adjusted to pH
3.5, 4.5, 5.5, and 6.5 each time, in 4 sets of duplicate
tubes. The mean percentage recovery (calculated
by comparing the area ratio of extracted samples to
the area ratio of standard samples) and the standard
deviation of warfarin extracted from each tube was
then calculated and compared.
(l) Optimisation of the type of organic solvent used
for LLE
Using the most suitable plasma pH determined
above, the optimisation of LLE was further carried
out by varying the type of organic solvent. In this
experiment, diethyl ether was replaced with 1) ethyl
acetate, 2) dichloromethane, 3) chloroform, and 4)
diethyl ether and n-hexane (2:1).

Resolution (Rs) = (tR2 – tR1)/([Wb2 + Wb1]/2),
Tailing factor (Tf ) = W0.05/2f,
Plate count (N) = 5.546(tR/W1/2)2.
Here, tR1 = retention time of the first analyte, tR2
= retention time of second analyte, Wb1 = base width
of the first analyte, Wb2 = base width of the second
analyte, W0.05 = peak width at 5% of the peak height,
f = front width at the peak base, W1/2 = peak width at
½ of the peak height, and tM = void time.
Results and discussion
A new optimised method suitable for the routine
analysis of plasma warfarin in human samples was
successfully developed.
Theoretically, warfarin, which is an acidic
compound, will be ionised when the pH of the buffer
solution is increased above its pKa value. This will
lead to its early elution from a reversed-phase system
(16). Another technique is to use a mobile phase pH
that has been adjusted to 2 units above and below its
pKa values (the pKa of warfarin is 5.0) (17). In this
experiment, 5 buffer solutions with different pH
levels were tested. However, when buffer solution
of pH 3.5, 4.5, and 5.5 were used, warfarin was not
eluted even after 30 min of total analytical time. It
is possible that at these 3 pH levels, warfarin is not
sufficiently ionised and therefore binds strongly to
the stationary phase. Both pH 6.5 and 7.5 are suitable
as they produced tall warfarin peaks within 30 min
(Figure 1). However, even though buffer solution
of pH 7.5 gave an earlier retention time, pH 6.5 was
selected because it produced a larger peak area for
warfarin.
ACN was favoured as the organic solvent because
it produced a significantly earlier retention time and
sharper peak (Figure 2). This may be attributed to
its higher solvent strength (18). The low viscosity of
ACN is an additional advantage over MeOH (18),
which produces a lower system pressure (2384 psi)
on the chromatographic system when compared to
MeOH (3065 psi).
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Figure 1. Superimposed warfarin peaks when the pH of the KH2PO4 buffer was adjusted
to (a) 7.5 and (b) 6.5. Warfarin peaks were not detected when the pH was
adjusted to 5.5 (c) and 6.5 (d).
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Figure 2. Superimposed warfarin peaks when (a) ACN and (b) MeOH were used as the
mobile phase. MeOH gave an average system pressure of 3065 psi while ACN’s
was lower at 2384 psi.

A higher proportion of organic solvent tends to
increase the mobile phase’s solvent strength (19).
Due to this fact, it was not surprising that the 40:60
composition of organic solvent and buffer gave a
faster retention time. However, warfarin’s peak area
was similar to that of a 30:70 composition. Due to
the fact that 40:60 is less economical since a higher
proportion of organic solvent is involved, the
composition of 30:70 was selected (Figure 3).
Using the right type of buffer solution is also a
pivotal part of the development of methodology.
From the 3 buffer solutions tested, the KH2PO4
buffer was selected because it gave the largest peak
area (Figure 4). Besides this, the pH of the mobile
phase previously selected (pH 6.5) fell within the
buffering range of phosphate buffers (pH 1.8-3.5 and
934

pH 5.8-8.0) (19). This is desirable because a mobile
phase buffer with the correct buffering range tends to
resist pH changes more efficiently and therefore may
reduce analytical variations.
Theoretically, increasing the buffer concentration
tends to allow polar samples to elute faster (18).
However, this was not true for warfarin, perhaps
due to the fact that it is a weakly polar compound.
Too high a buffer concentration may also be harmful
as it can form hard crystals abrasive to pump seals
(20). In this experiment, even though a buffer salt
concentration of 0.05 M gave the highest peak area
for warfarin (Figure 5), a lower concentration of 0.01
M, which produced an earlier retention time, was
selected as it is also economical and may preserve
column life in the long run.
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Figure 3. Superimposed warfarin peaks when the composition of the mobile phase was
(a) 40:60 and (b) 30:70.
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Figure 4. Superimposed warfarin peaks when (a) CH3COOK, (b) NaH2PO4, and (c)
KH2PO4 were used as the buffer solutions.
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Figure 5. Superimposed warfarin peaks when the buffer concentration was adjusted to
(a) 0.01 M, (b) 0.05 M, and (c) 0.1 M.

Lehrer (21) stated that a suitable internal standard
should: 1) be completely resolved from all peaks in the
sample, 2) be eluted near the analyte, 3) behave similarly
to the analyte in pretreatment so that losses can be
corrected, 4) have a peak area approximately equal

to the standard in the concentration desired, 5) not
normally be present in the sample, 6) be commercially
available in a pure form, and 7) be easily added as
a liquid. The search for an internal standard was
carried out based on these principles. Previous reports
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recommended the use of preextraction spiked internal
standard methods (8,9,13). In our investigation,
however, a high but false percentage recovery was
obtained when using this method. We found the
postextraction spiked internal standard method to
have a similar analytical bias to the preextraction
spiked internal standard, as also shown by Reagen et
al. (22). Therefore, the simpler preextraction spiked
internal standard method was selected.
During the determination of the suitable
candidates for the internal standard, we found that
the peaks of diethylstilbestrol and lignocaine did not
appear when injected by using the developed HPLC
condition (Figure 6). Sulphadiazine’s peak coeluted
with the solvent front while indomethacin showed
a relatively long retention time of 26 min. Eserine’s
peak may coelute with warfarin as it appeared at
7.87 min, which is very close to warfarin’s retention
time. Therefore, phenylbutazone was selected as the
internal standard of choice because its peak did not
coelute with the solvent front or warfarin’s peak.
Furthermore, it showed an acceptable retention time
and a symmetrical peak.
Higher column temperatures tend to lower mobile
phase viscosities, which is desirable because a lower
systemic pressure is produced (18). This will allow a
lower linear velocity for the chromatographic system
and produce a sharper peak (14). The heat will also
provide some kinetic energy to the samples to propel
them faster within the column, thereby decreasing
the total analytical time (18). A column temperature
of 30 °C was finally selected because it gave a faster
retention time without compromising the peak area

(Figure 7). A higher temperature than this was not
tested in order to preserve column life since high
temperatures may be detrimental to the column’s
packing when used over time.
Increased flow rates tend to shorten retention
time, but at the same time may contribute to band
broadening and a decrease in the column’s efficiency
(19). Even though both flow rates of 0.5 and 0.75 mL/
min produced significantly larger peak areas than
1.0 mL/min did, they were not chosen because of the
increase in retention time. In fact, the retention time at
0.5 mL/min was double that at 1.0 mL/min (Figure 8).
The function of an organic modifier is mainly to
reduce peak tailing. In this experiment, acetic acid
(1%) was added because, theoretically, an acetate
organic modifier will decrease the band-broadening
effect for acidic compounds such as warfarin (19).
However, we found that it was not useful to add
1% acetic acid as it produced baseline noises while
reducing warfarin’s peak area to about one-third, and
it even increased the retention time (Figure 9).
The use of a photodiode UV detector is
advantageous as it allows for the viewing and
selection of wavelengths in real time. This will greatly
minimise the duration of method development.
From our analyses, we found that a broad-spectrum
range such as 190-800 nm tends to be suitable for the
analysis of concentrated samples (such as warfarin
at 100 μg/mL), but it produced larger baseline
noises and was therefore unable to detect lower
concentrations of warfarin (such as a concentration
of 500 ng/mL) (Figure 10). In order to eliminate
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Figure 6. Superimposed chromatograms when sulphadiazine (SDZ), eserine (ESR),
phenylbutazone (PBZ), and indomethacin (IND) were injected into the HPLC
system. Diethylstilbestrol (DSB) and lignocaine (LNC) were not eluted when
injected under similar chromatographic conditions.
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warfarin and phenylbutazone in this test were 100 μg/mL.
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Figure 10. Chromatograms produced when the PDA detection spectrum range was set at a) 280 nm, b) 290 nm, c) 300 nm, d) 309.4
nm, and e) 190-800 nm. The concentrations of warfarin and phenylbutazone in this test were 500 ng/mL and 20 μg/mL,
respectively.
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Common pretreatment methods for warfarin
are LLE and SPE. To ensure that the consistency of
the results is not affected by day-to-day instrument
variations, an internal standard is often employed
(14). By far, the most popular internal standard
method for warfarin analysis is the preextraction
spiked internal standard, where the internal standard
is added into the biological sample before the
extraction process. In contrast, the postextraction
internal standard method requires the addition of
the internal standard compound after the extraction
process is completed.
A preextraction method has the advantage of
being able to compensate for sample loss during
sample pretreatment (14). The postextraction
method, while it may not incur the same advantages
as the preextraction method, is much easier to
carry out because the optimisation of the extraction
process is only required for warfarin instead of both
warfarin and the internal standard. Furthermore,
the advantage of a preextraction method will only
materialise if the chosen internal standard behaves
similarly to the analyte in pretreatment (21), which
means that the recovery of warfarin and the potential
internal standard must be similar. However, in reality,
the search for such an ideal internal standard can be
difficult and time-consuming. Locatelli et al. (23)
managed to obtain a similar recovery for racemic
warfarin and their selected internal standard, albeit
at lower percentage recoveries (below 80%).
In a new HPLC method development, the
extraction step is also very important as it can affect
the sensitivity of the overall analysis. Since pH 4.5
gave the largest percentage recovery for warfarin, it
was selected as the pH of choice for the subsequent
LLE method investigation (Figure 11).
With the pH of the plasma fixed at 4.5, the effects
of using different organic solvents for warfarin
extraction were further investigated. The combination
of n-hexane and diethyl ether yielded the highest
percentage recovery (89.96%) for warfarin (Figure
12). This may be due to the low polarity nature of

100

90.36

84.65
Mean % recovery

baseline noise generated by endogenous compounds
in plasma samples, it is preferable to do a single-point
absorbance, which is more specific. Finally, 300 nm
was determined to be the best UV wavelength for the
detection of both warfarin and phenylbutazone.

77.58

80

73.32

60
40
20
pH

0
3
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5

5.5

6

6.5

7

Figure 11. Mean percentage recoveries of warfarin at different
plasma pH levels. The sample was extracted by using
diethyl ether as the organic solvent.

n-hexane (polarity index = 0.1), which can attract the
less polar warfarin compound from the aqueous layer
more effectively than by more polar organic solvents
such as ethyl acetate (polarity index = 4.4) (24).
However, since n-hexane and diethyl ether have very
different boiling points (69 °C and 35 °C, respectively)
(24), they are not practical to use. Therefore, diethyl
ether alone (which was the second-best alternative at
88.24%) was selected. Warfarin was extracted using
2 volumes of 2.5 mL of the organic solvent instead
of using 1 large volume of 5 mL because a repeated
small-volume extraction is said to yield a better
recovery than a single large-volume extraction (25).
The final optimised chromatography method met
the system suitability parameters requirement as
outlined by the FDA (Table 1). The limit of detection
was 20 ng/mL. The method was successfully tested by
analysing plasma samples spiked with 100 μg/mL of
warfarin and the internal standard (Figure 13).
To summarise, the HPLC detection of warfarin
in plasma was accomplished at 300 nm with a
30:70 (v/v) ACN and KH2PO4 buffer solution
(0.01 M) as the final mobile phase. The pH of the
buffer solution was adjusted to 6.5 and the internal
standard of choice was phenylbutazone, which was
spiked postextraction. The column temperature was
maintained at 30 °C and the flow rate was 1.0 mL/
min. By using these optimised chromatographic
conditions, the average retention times of warfarin
and phenylbutazone were 7 and 11 min, respectively,
with a total run time of 14 min following a 10μL injection. The postextraction spiked internal
standard method saves a significant amount of
939
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Figure 12. Mean percentage recoveries of warfarin and their standard deviations
when the sample was extracted using different organic solvents with pH
fixed at 4.5.

Table. System suitability parameters.
Warfarin

FDA requirements

Resolution (R s )

3.33

>2.0

Tailing factor (Tf )

1.86

≤2.0

Plate count (N)

2550

>2000

0.07
0.06

Peak area:
(WAR) 1 613 399
(PBZ) 428 033

WAR

66.430
4

Parameters

AU

0.05
0.04

9.971

0.03
0.02
0.01

PBZ

0.00
2.0

4.0

6.0

8.0

10.0

12.0

14.0

Min

Figure 13. Representative chromatogram of plasma warfarin and phenylbutazone
extracted by using the optimised LLE method with the optimised
chromatographic condition. The concentrations of both warfarin and
phenylbutazone in this test were 100 μg/mL.

time. Furthermore, this method gave a percentage
recovery of nearly 90% and is cost-efficient. On the
whole, the method is simple, economical, and allows
both warfarin and phenylbutazone to achieve good
resolutions, producing chromatograms that comply
with the FDA’s guideline.
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